Study on the value of daglizin in treating patients with heart failure
达格列净治疗心衰患者的价值研究

摘要

目的 讨论在心衰患者中应用达格列净治疗的临床价值。方法 选取2021年10月-2022年10月我院治疗的心衰患者80例，根据随机分组原则将其分为2组，对照组（40例，传统抗心衰治疗），研究组（40例，传统抗心衰治疗+达格列净治疗）。将患者治疗后的心功能、炎症水平和治疗效果作为评估疗效的主要指标。结果 与对照组相比：治疗后研究组LVIDs、LVIDd和IL-6、CRP更低，LVEF水平、6分钟步行测估距离和治疗有效率更高（P＜0.05）。结论 在对心衰患者进行传统治疗时使用达格列净治疗可显著改善患者的心功能状况，降低其炎症反应，提高整体治疗效果，从而预防患者疾病复发情况的风险。

Abstract

Objective To discuss the clinical value of using dapagliflozin treatment in patients with heart failure.
Methods 80 patients with heart failure treated in our hospital from October 2021 to October 2022 were selected and randomly divided into two groups: a control group (40 cases, traditional anti heart failure treatment) and a study group (40 cases, traditional anti heart failure treatment+dapagliflozin treatment). The main indicators for evaluating the therapeutic effect are the patient's heart function, inflammation level, and treatment effect after treatment.
Results Compared with the control group, the study group had LVIDs after treatment LVIDd and IL-6 CRP is lower, LVEF level, 6-minute walking distance estimation, and treatment effectiveness were higher (P<0.05).
Conclusion   The use of dapagliflozin in traditional treatment for heart failure patients can significantly improve their cardiac function, reduce their inflammatory response, improve overall treatment efficacy, and thus prevent the risk of disease recurrence in patients.